Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-09-26FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for levetiracetam (ANDA 078993), approving a generic version of the anti-seizu…
-
FDA label_change · 2014-09-26FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approves a supplemental application for lamotrigine from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2014-09-26FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for a generic levetiracetam product from Lupin Pharmaceuticals, Inc. (ANDA 078154).
-
FDA approval · 2014-09-24FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for levetiracetam from Mylan Pharmaceuticals Inc., granting a supplemental approval under the ANDA f…
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures [Phase 2, Phase 3]
This clinical trial update reports on the safety and tolerability of intravenous SPM 927 as a replacement for oral SPM 927 in subjects with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization [Phase 3]
A Phase 3 trial evaluating SPM 927 as adjunctive therapy for partial seizures (with or without secondary generalization) completed, sponsore…
-
FDA approval · 2014-09-19FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Divalproex Sodium by BluePoint Laboratories, indicating clearance of a supplemental filing for a…
-
FDA approval · 2014-09-18FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Torrent Pharmaceuticals Limited for levetiracetam. This marks an approval of a supplemental fili…
-
CLINICAL_TRIALS trial_result · 2014-09-17Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression [NA]
A completed study evaluated adding Wuling Capsule to standard therapy for patients with epilepsy and depression.
-
FDA approval · 2014-09-16FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) submitted by Novartis Pharmaceuticals Corporation. The action updat…
-
FDA approval · 2014-09-16FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) from Novartis Pharmaceuticals Corporation, resulting in updated labe…
-
CLINICAL_TRIALS trial_result · 2014-09-16Clinical Trial Update: Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol [EARLY_Phase 1]
Early Phase 1 trial evaluating tissue distribution of orally administered natural vitamin E tocotrienol across subjects with end-stage heart…
-
CLINICAL_TRIALS trial_result · 2014-09-08Clinical Trial Update: Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures [Phase 3]
A Phase 3 trial evaluating two doses of immediate-release retigabine (900 mg/day and 600 mg/day) as adjunctive therapy in adult Asian subjec…
-
CLINICAL_TRIALS trial_result · 2014-09-04Clinical Trial Update: Study in Pediatric Subjects With Epilepsy [Phase 2]
Phase 2 clinical trial in pediatric epilepsy subjects was terminated; results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: IVIG Treatment for Refractory Immune-Related Adult Epilepsy [Phase 2]
Phase 2 trial of intravenous immunoglobulin (IVIG) for refractory immune-related epilepsy was terminated. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 [Phase 2]
Phase 2 clinical trial update on pharmacokinetics, efficacy, and tolerability of BIA 2-093 in epilepsy completed with results posted in 2014…
-
FDA approval · 2014-08-29FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., indicating an approval of a supplement to the drug’s…
-
FDA approval · 2014-08-29FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in a label update.
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents [Phase 3]
Phase 3 clinical study of lamotrigine for newly diagnosed typical absence seizures in children and adolescents has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia
A completed clinical trial update investigates why patients are not taking home anti-convulsant medications before surgery or procedures inv…
-
FDA approval · 2014-08-18FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) by Parke-Davis (Pfizer), resulting in updated labeling.
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) by UCB, Inc., authorizing changes to the labeling and/or addition of indicat…
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The action updates the product labeling with the new …
-
CLINICAL_TRIALS trial_result · 2014-08-12Clinical Trial Update: A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures [Phase 3]
Phase 3 study of levetiracetam in Japanese pediatric patients with generalized tonic-clonic seizures has completed. Results have been posted…
-
CLINICAL_TRIALS trial_result · 2014-08-12Clinical Trial Update: A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 [Phase 2]
A phase 2, placebo-controlled trial evaluating the safety and efficacy of BIA 2-093 in epilepsy has completed and results have been posted.